Medical Costs, Health Care Utilization, and Productivity Losses Associated With Hypertension by COVID-19 Among US Commercial Enrollees - Lee, Jun Soo; Zhang, Yidan (Xue); Wang, Yu; Park, Joohyun; Kumar, Ashutosh; Donald, Bruce; Luo, Feijun; Roy, Kakoli (medRxiv, 2024)
Background Hypertension is a major risk factor for cardiovascular and renal diseases, significantly contributing to morbidity and mortality. The COVID-19 pandemic has heightened concerns about the impact of hypertension on severe COVID-19 outcomes.Methods We conducted a cross-sectional analysis using the 2021 MarketScan Commercial and Health and Productivity Management databases. The study included adults aged 18-64 with continuous employer-sponsored private insurance, excluding those with pregnancy or capitated plans. We compared excess total medical costs, healthcare utilization (including the number of emergency department visits, inpatient admissions, outpatient visits, and outpatient prescription drugs), and productivity losses and related costs due to sick absences, short-term disability (STD), and long-term disability (LTD) between individuals with and without hypertension, further stratified by COVID-19 diagnosis. Multivariate regression models adjusted for demographics and comorbidities were used to estimate the differences in outcomes.Results Among 1,612,398 adults aged 18-64 years, 13% had hypertension in 2021. Those with hypertension were older, were less likely to be female or live in urban areas, and exhibited a higher prevalence of comorbidities. The total excess medical costs associated with hypertension were $8723 per patient (95% CI, $8352-$9093), which was significantly higher by $6117 (95% CI, $4780-$7453) among individuals diagnosed with COVID-19. Persons with hypertension had higher health care utilization, including a higher number of ED visits (0.21 per patient; 95% CI, 0.21-0.22), inpatient admissions (0.11; 95% CI, 0.10-0.12), outpatient visits (5.42; 95% CI, 5.36-5.49), and outpatient prescription drugs (10.85; 95% CI, 10.75-10.94). Moreover, they experienced a greater number of sick absences (1.22 days; 95% CI, 1.07-1.36) and STD occurrences (3.68 days; 95% CI, 3.38-3.98) per patient compared to those without hypertension. These trends were further exacerbated among individuals diagnosed with COVID-19.Conclusions Hypertension markedly increases medical costs, healthcare utilization, and productivity losses, which are further exacerbated by COVID-19. These findings highlight the substantial economic burden of managing hypertension in the context of the COVID-19 pandemic and underscore the importance of targeted interventions.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study is not based on a clinical trial.Funding StatementThe authors received no financial support for the research, authorship, and/or publication of this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data were de-identified, and the study was exempt from review by the Institutional Review Board of the Centers for Disease Control and Prevention.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe authors cannot share the data publicly due to the data user agreement, but the program codes are available upon request to the corresponding author.